Company / Working Capital
Jade Biosciences, Inc. Working Capital History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$76.3M
FY2024
5-year range
$2.9M / $171.8M
FY2020-FY2024
Trend
-28.4%
vs FY2023
Sector context
#195 of 214
Health Care
What the data says
Among 214 Health Care companies, Jade Biosciences, Inc. is in the bottom 9% for working capital. Working Capital has declined for 3 consecutive years, from $172M in FY2021 to $76M in FY2024.
Based on SEC 10-K filings.
$76M in FY2024 with a 3-year CAGR of -23.7%.
Declined from $124M to $76M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -23.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 214This company $76.3M Sector average $955.5M
▼
-92.0% below sector average
Key checks
Key Insights
- Jade Biosciences, Inc.'s working capital has declined for 3 consecutive years.
- 3-year CAGR of -23.7%, indicating a declining trend.
- In FY2024, working capital decreased 28.4% year-over-year.
- Ranks #195 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.03 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $76.3M | -28.4% |
| FY2023 | $106.6M | -13.8% |
| FY2022 | $123.7M | -28.0% |
| FY2021 | $171.8M | +5819.5% |
| FY2020 | $2.9M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026